Latest Breaking News On - பேட்ரிக் மூனி - Page 18 : comparemela.com

Published: Mar 03, 2021   HADDONFIELD, N.J., March 3, 2021 /PRNewswire/ Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that on March 2, 2021 the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 10,934,277 ( 277 patent) covering various embodiments of the pharmaceutical composition of matter for the company s lead compound, LNS8801. Linnaeus s patent disclosure is directed toward the pharmaceutical composition of matter of LNS8801 and generally embodies (1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts, and co-crystals, that modulates G protein-coupled estrogen receptor activity; (2) pharmaceutical and cosmetic compositions comprising an enantiomerically purified SRR G-1, or a derivative thereof; and (3) methods of treating or preventing

Patrick mooneyTrademark officeLinnaeus therapeutics incPrnewswire linnaeus therapeutics incUniversity of pennsylvania penn centerPenn centerLinnaeus therapeutics announces issuance of composition matter patent for lns8801 by the us and trademark officeபேட்ரிக் மூனிமுத்திரை அலுவலகம்பல்கலைக்கழகம் ஆஃப் பென்சில்வேனியா பென் மையம்பென் மையம்